hiss, Author at HISS

27 December, 2022

Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the SAVE-MORE randomised trial

2024-04-03T12:43:50+03:00By hiss|Categories: Publications, Therapeutics|Tags: Anakinra, clinical trial, COVID-19, suPAR|

Karolina Akinosoglou, Antigone Kotsaki, Ioanna-Maria Gounaridi, Eirini Christaki, Simeon Metallidis, Georgios Adamis, Archontoula Fragkou, Massimo Fantoni, Aggeliki Rapti, Ioannis Kalomenidis, Georgios Chrysos, Gloria Boni, Ilias Kainis, Zoi Alexiou, Francesco Castelli, Francesco Saverio Serino, Petros Bakakos, Emanuele Nicastri, Vassiliki Tzavara, Asimina Safarika, Sofia Ioannou, Lorenzo Dagna, Katerina Dimakou, Glykeria Tzatzagou, Maria Chini, Matteo Bassetti, Vasileios

27 December, 2022

Oral minocycline plus rifampicin versus oral linezolid for complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: The AIDA open label, randomized, controlled Phase 4 trial

2024-04-03T12:38:22+03:00By hiss|Categories: Publications, Therapeutics|Tags: clinical trial, skin infections|

Antigone Kotsaki, Nikolaos Tziolos, Theano Kontopoulou, Ioannis M. Koutelidakis, Styliani Symbardi, Vaughan Reed, Miriam O’Hare, Zoi Alexiou, Helen Sambatakou, Konstantinos Toutouzas, Karolina Akinosoglou, Malvina Lada, Evangelos J. Giamarellos-Bourboulis, and Alasdair MacGowan eClinicalMedicine Volume 56, 101790, February 01, 2023 DOI: 10.1016/j.eclinm.2022.101790Download pdf 🡇 Funding The EU Seventh Research Framework Programme. Keywords: Minocycline; Rifampicin;

21 December, 2022

ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol

2024-04-02T18:40:49+03:00By hiss|Categories: Publications, Therapeutics|Tags: clinical trial, Sepsis, SOFA|

Antigone Kotsaki, Peter Pickkers , Michael Bauer, Thierry Calandra, Mihaela Lupse, W Joost Wiersinga, Sylvain Meylan , Frank Bloos, Tom van der Poll, Marleen A Slim , Niels van Mourik, Marcella C A Müller, Lonneke van Vught,8 Alexander P J Vlaar, Aline de Nooijer, Lieke Bakkerus, Sebastian Weis, Nikolaos Antonakos, Mihai G Netea, Evangelos

21 December, 2022

Press conference of the results of the SAVE-MORE trial

2022-12-21T10:18:44+03:00By hiss|Categories: Interviews|

“Press conference of the results of SAVE-MORE trial” ERT Interview, September 2021

21 December, 2022

Interview with the Evangelos Giamarellos-Bourboulis for the Phase 3 SAVE-MORE Study

Interview with the Evangelos Giamarellos-Bourboulis for the Phase 3 SAVE-MORE Study

2022-12-21T10:19:47+03:00By hiss|Categories: Interviews|

Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

19 December, 2022

Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia

2024-04-02T18:36:36+03:00By hiss|Categories: Pathogenesis, Publications|Tags: Anakinra, clinical trial, COVID-19|

Charilaos Samaras, Evdoxia Kyriazopoulou, Garyfallia Poulakou, Eran Reiner, Maria Kosmidou, Ioanna Karanika, Vasileios Petrakis, George Adamis, Nikolaos K. Gatselis, Archontoula Fragkou, Aggeliki Rapti, Eleonora Taddei, Ioannis Kalomenidis, George Chrysos, Giulia Bertoli, Ilias Kainis, Zoi Alexiou, Francesco Castelli, Francesco Saverio Serino, Petros Bakakos, Emanuele Nicastri, Vassiliki Tzavara, Evangelos Kostis, Lorenzo Dagna, Sofia Koukidou, Glykeria Tzatzagou,

8 November, 2022

Evangelos J. Giamarellos-Bourboulis

Evangelos J. Giamarellos-Bourboulis

2022-12-19T16:50:58+03:00By hiss|Categories: Executive Board|

He graduated from the National and Kapodistrian University of Athens Medical School in 1994, where he also completed his PhD in 1998 entitled “The in vitro activity of polyunsaturated fatty acids on Gram-negative bacteria”. He finished his training in Internal Medicine in Laikon Athens Hospital in 2001 and he was specialized in the immunology of

7 November, 2022

A randomized clinical trial of lipid metabolism modulation with fenofibrate for acute coronavirus disease 2019

2023-02-16T12:33:18+03:00By hiss|Categories: Publications|Tags: clinical trial, COVID-19, metabolism|

Julio A Chirinos, Patricio Lopez-Jaramillo, Evangelos J. Giamarellos-Bourboulis, Gonzalo H Dávila-Del-Carpio, Abdul Rahman Bizri, Jaime F Andrade-Villanueva, Oday Salman, Carlos Cure-Cure, Nelson R Rosado-Santander, Mario P Cornejo Giraldo, Luz A González-Hernández, Rima Moghnieh, Rapti Angeliki, María E Cruz Saldarriaga, Marcos Pariona, Carola Medina, Ioannis Dimitroulis, Charalambos Vlachopoulos, Corina Gutierrez, Juan E Rodriguez-Mori, Edgar Gomez-Laiton,

1 November, 2022

Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial

2024-04-02T18:31:09+03:00By hiss|Categories: Multicenter studies in Greece, Publications|Tags: Anakinra, clinical trial, Sepsis|

Konstantinos Leventogiannis, Evdoxia Kyriazopoulou, Nikolaos Antonakos, Antigone Kotsaki, Iraklis Tsangaris, Dimitra Markopoulou, Inge Grondman, Nikoleta Rovina, Vassiliki Theodorou, Eleni Antoniadou, Ioannis Koutsodimitropoulos, George Dalekos, Glykeria Vlachogianni, Karolina Akinosoglou, Vassileios Koulouras, Apostolos Komnos, Theano Kontopoulou, Athanassios Prekates, Antonia Koutsoukou, Jos WM van der Meer, George Dimopoulos, Miltiades Kyprianou, Mihai G Netea, Evangelos J. Giamarellos-Bourboulis

10 October, 2022

INSPIRE

2024-11-04T11:14:45+03:00By hiss|Categories: Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: Anakinra, pneumonia|

Ongoing study Official Study Title Immunotherapy Navigated by Serum Presepsin for Infections of the REspiratory tract: the INSPIRE double-blind, randomized, phase IIa exploratory trial Brief Description The INSPIRE study is an exploratory, randomised, phase IIa clinical trial which aims to evaluate the potential benefit of presepsin-guided anakinra therapy as an adjuvant to the standard

About hiss